GFPT1 and Patent ductus arteriosus: Pharmacological GFPT1 inhibition, or blockade of glutamine utilization through DON treatment, heightens PDA sensitivity to anti-PD-1 therapy by diminishing hyaluronan levels and altering the extracellular matrix (ECM) [165].